Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
AssigneeGilead Sciences, Inc.
InventorsScott Ellis, Davin S. Rautiola, Dustin S. Siegel, Maria M. Toteva, Adelle A. Vandersteen
Life of this patent
Estimating the term…
Abstract
The present disclosure provides pharmaceutical formulations of the compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, and an aqueous vehicle. The pharmaceutical formulations of the disclosure are useful in treatment and prevention of viral infections in subjects in need thereof and are for administration by inhalation.
Claims44
A pharmaceutical formulation comprising:
- i. a compound of Formula I, Formula Ia, or Formula Ib:
- or a pharmaceutically acceptable salt thereof;
- and
- ii. an aqueous vehicle;
- wherein the pharmaceutical formulation is suitable for administration via inhalation.
A pharmaceutical formulation comprising:
- i. a compound of Formula I:
- or a pharmaceutically acceptable salt thereof;
- and
- ii. an aqueous vehicle;
- wherein the pharmaceutical formulation is suitable for administration via inhalation.
A pharmaceutical formulation comprising:
- i. a compound of Formula Ia:
- or a pharmaceutically acceptable salt thereof;
- and
- ii. an aqueous vehicle;
- wherein the pharmaceutical formulation is suitable for administration via inhalation.
A pharmaceutical formulation comprising:
- i. a compound of Formula Ib:
- or a pharmaceutically acceptable salt thereof;
- and
- ii. an aqueous vehicle;
- wherein the pharmaceutical formulation is suitable for administration via inhalation.
5-49. (canceled)
A pharmaceutical formulation comprising:
- i. a compound of Formula I, Formula Ia, or Formula Ib:
- or a pharmaceutically acceptable salt thereof;
- ii. water;
- and
- iii. cyclodextrin;
- wherein the pharmaceutical formulation is suitable for administration via inhalation.
(canceled)
(canceled)
(canceled)
-66. (canceled)
(canceled)
(canceled)
(canceled)
-81. (canceled)
A method of treating or preventing a viral infection in a human in need thereof, comprising administering to the human a reconstituted lyophilized formulation by inhalation;
- wherein the lyophilized pharmaceutical formulation comprises:
- i. a compound of Formula I, Formula Ia, or Formula Ib:
- or a pharmaceutically acceptable salt thereof;
- and
- ii. cyclodextrin.
-91. (canceled)
-95. (canceled)
(canceled)
A lyophilized formulation comprising:
- (i) a compound of Formula I, Formula Ia, or Formula Ib in an amount of 5% to 10% w/w;
- and
- (ii) cyclodextrin in an amount of from 90% to 95% w/w.
-102. (canceled)
-105. (canceled)
Dependencies are inferred from the claim text.